ATLAS // A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation ACT4ALS-MNDPhase 3Individuals with ALS risk mutations Follow-Up (recruiting ended)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS ACT4ALS-MNDSLAPhase 2 Interrupted
IASO | Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With ALS ACT4ALS-MNDPhase 1b pilot trialALS Completed
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS SLAPhase 3 Research results available
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients ACT4ALS-MNDSLAPhase 3 Suspended recruitment
